State-transition modeling of blood transcriptome predicts disease evolution and treatment response in chronic myeloid leukemia
Leukemia, Published online: 02 February 2024; doi:10.1038/s41375-024-02142-9State-transition modeling of blood transcriptome predicts disease evolution and treatment response in chronic myeloid leukemia (Source: Leukemia)
Source: Leukemia - February 2, 2024 Category: Hematology Authors: David E. Frankhouser Russell C. Rockne Lisa Uechi Dandan Zhao Sergio Branciamore Denis O ’Meally Jihyun Irizarry Lucy Ghoda Haris Ali Jeffery M. Trent Stephen Forman Yu-Hsuan Fu Ya-Huei Kuo Bin Zhang Guido Marcucci Source Type: research
Correlation analysis of bone marrow microvessel density and miRNA expression on drug resistance in patients with chronic myelogenous leukemia after tyrosine kinase inhibitor treatment
CONCLUSION: MVD and the expression of miR-340 and miR-155 are closely associated with CML resistance after TKI treatment.PMID:38299685 | DOI:10.1080/16078454.2024.2304488 (Source: Hematology)
Source: Hematology - February 1, 2024 Category: Hematology Authors: Yi-Gang Guo Lu-Lu Zhang Ping Hu Zhang-Zhi Li Rui-Bo Zhang Xi Lv Qiong Yi Ling-Bo Zhan Xue-Lian Feng Source Type: research
Addition of Myeloablative Doses of Total Marrow Irradiation (TMI) to Myeloablative Fludarabine/Busulfan Conditioning for Allogeneic HSCT in Patients with High-Risk AML, CML, or Myelodysplastic Syndrome: A Phase II Clinical Trial
In allogeneic hematopoietic stem cell transplantation (HSCT) for high-risk myeloid disorders, the intensity of the conditioning regimen correlates with the risk of relapse, but its benefit may be offset by its risk of toxicity.From 2017 to 2023, 31 patients with high-risk acute myeloid leukemia (AML, n=20) or myelodysplastic syndrome (MDS, n=5), or chronic myeloid leukemia (CML, n=3) in accelerated phase or blast crisis, were enrolled into a prospective phase II clinical trial of allogeneic HSCT using myeloablative TMI at 9Gy in combination with standard myeloablative fludarabine and targeted IV busulfan (FluBu4) chemother...
Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Lucas Maahs, Matthew Koshy, Karen Sweiss, Kang-hyun Ahn, Zhengjia Chen, Chukwuemeka Uzoka, Carlos Galvez, Paul Rubinstein, John Quigley, Santosh L Saraf, Ana Avila Rodriguez, Bulent Aydogan, Nadim Mahmud, Damiano Rondelli Tags: 209 Source Type: research
GSE254285 T cell Immune Escape in Blast Crisis Transformation of Chronic Myeloid Leukemia
Contributors : Bin Zhang ; Min-Hsuan ChenSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusChronic myeloid leukemia (CML) may transform from a chronic phase (CP) into blast crisis (BC), which is often incurable. Herein, we report that miR-142 deficit acquired by T lymphocytes contributes to BC transformation by promoting immune escape. We observe that T cells of BC patients lack miR-142 and are fewer and exhausted compared with CP patients. Similarly, BC miR-142 −/−/BCR/ABL+/+ mouse presents with T lymphopenia compared with the CP miR-142+/+/BCR/ABL+/+ mouse. In the BC mouse, miR-...
Source: GEO: Gene Expression Omnibus - January 31, 2024 Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Mus musculus Source Type: research
Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials
Leukemia, Published online: 29 January 2024; doi:10.1038/s41375-024-02159-0Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials (Source: Leukemia)
Source: Leukemia - January 29, 2024 Category: Hematology Authors: Elias Jabbour Jane Apperley Jorge Cortes Delphine Rea Michael Deininger Elisabetta Abruzzese Charles Chuah Daniel J. DeAngelo Andreas Hochhaus Jeffrey H. Lipton Michael Mauro Franck Nicolini Javier Pinilla-Ibarz Gianantonio Rosti Philippe Rousselot Neil P Source Type: research
Immortalised chronic myeloid leukemia (CML) derived mesenchymal stromal cells (MSCs) line retains the immunomodulatory and chemoprotective properties of CML patient-derived MSCs
Cell Signal. 2024 Jan 27;116:111067. doi: 10.1016/j.cellsig.2024.111067. Online ahead of print.ABSTRACTDespite the success of Tyrosine kinase inhibitors (TKIs) in treating chronic myeloid leukemia (CML), leukemic stem cells (LSCs) persist, contributing to relapse and resistance. CML Mesenchymal Stromal Cells (MSCs) help in LSC maintenance and protection from TKIs. However, the limited passage and self-differentiation abilities of primary CML MSCs hinder extensive research. To overcome this, we generated and characterized an immortalised CML patient-derived MSC (iCML MSC) line and assessed its role in LSC maintenance. We al...
Source: Cellular Signalling - January 28, 2024 Category: Cytology Authors: Esther Sathya Bama Benjamin Elizabeth Vinod Raveen Stephen Stallon Illangeswaran Bharathi M Rajamani Rakhi Thalayattu Vidhyadharan Abhirup Bagchi Arnab Maity Ajith Mohan Ganesh Parasuraman Soosai Manickam Amirtham Aby Abraham Shaji R Velayudhan Poonkuzhal Source Type: research
Effect of Tyrosine Kinase Inhibitor Therapy on Estimated Glomerular Filtration Rate in Patients with Chronic Myeloid Leukemia
CONCLUSION: Imatinib could result in a decline in eGFR which was clinically similar to early-stage CKD patients. We did not observe significant kidney function deterioration in patients receiving 2GTKIs including dasatinib and nilotinib. We recommend close renal function monitoring in patients receiving imatinib, especially for elderly patients with lower baseline eGFR and hypertension.PMID:38281820 | DOI:10.1016/j.clml.2023.12.004 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - January 28, 2024 Category: Cancer & Oncology Authors: Özge Sönmez Nurg ül Özgür Yurttaş İlker İhtiyaroğlu Halil Mete Çakır Zeynep Atl ı Tu ğrul Elverdi Ay şe Salihoğlu Nurhan Seyahi Muhlis Cem Ar Şeniz Öngören Zafer Ba şlar Teoman Soysal Ahmet Emre E şkazan Source Type: research
An Active Compound from the Pyrazine Family Induces Apoptosis by Targeting the Bax/Bcl2 and Survivin Expression in Chronic Myeloid Leukemia K562 Cells
(Source: Anti-Cancer Agents in Medicinal Chemistry)
Source: Anti-Cancer Agents in Medicinal Chemistry - January 28, 2024 Category: Cancer & Oncology Authors: Rostampour, Saeedeh Eslami, Farhad Babaei, Esmaeil Mostafavi, Hossein Mahdavi, Majid Tags: Research article Source Type: research
The impact of the BCR-ABL oncogene in the pathology and treatment of chronic myeloid leukemia
This article offers a comprehensive analysis of the structural attributes of BCR-ABL, emphasizing its pivotal role as a biomarker and therapeutic target in CML. It underscores the imperative for ongoing research to refine treatment modalities and enhance overall outcomes in managing CML.PMID:38280275 | DOI:10.1016/j.prp.2024.155161 (Source: Pathology, Research and Practice)
Source: Pathology, Research and Practice - January 27, 2024 Category: Pathology Authors: Mohamed El-Tanani Hamdi Nsairat Ismail I Matalka Yin Fai Lee Manfredi Rizzo Alaa A Aljabali Vijay Mishra Yachana Mishra Altijana Hromi ć-Jahjefendić Murtaza M Tambuwala Source Type: research
Bioassay-guided isolation of anti-leukemic steroids from Aglaia abbreviata by inducing apoptosis
In conclusion, our investigation implied that compound 14 may serve as a potential anti-leukemia agent.PMID:38280357 | DOI:10.1016/j.bioorg.2024.107147 (Source: Bioorganic Chemistry)
Source: Bioorganic Chemistry - January 27, 2024 Category: Chemistry Authors: Keying Liu Jue Yang Yunyan Tang Yanan Li Zhanxing Hu Xiaojiang Hao Ping Yi Chunmao Yuan Source Type: research
A Review of the Therapeutic Role of Bosutinib in Chronic Myeloid Leukemia
Clin Lymphoma Myeloma Leuk. 2024 Jan 12:S2152-2650(24)00022-3. doi: 10.1016/j.clml.2024.01.005. Online ahead of print.ABSTRACTThe development of the BCR::ABL1 tyrosine kinase inhibitors (TKIs) has transformed Philadelphia chromosome (Ph)-positive chronic myeloid leukemia (CML) from a fatal disease to an often-indolent illness that, when managed effectively, can restore a life expectancy close to that of the normal population. Bosutinib is a second-generation TKI approved for adults with Ph-positive CML in chronic phase, accelerated phase, or blast phase that is resistant or intolerant to prior therapy, and for newly diagno...
Source: Clinical Lymphoma and Myeloma - January 26, 2024 Category: Cancer & Oncology Authors: Hagop M Kantarjian Elias J Jabbour Jeffrey H Lipton Fausto Castagnetti Tim H Br ümmendorf Source Type: research
Treatment-free remission after a second TKI discontinuation attempt in patients with Chronic Myeloid Leukemia re-treated with dasatinib – interim results from the DAstop2 trial
Leukemia, Published online: 26 January 2024; doi:10.1038/s41375-024-02145-6Treatment-free remission after a second TKI discontinuation attempt in patients with Chronic Myeloid Leukemia re-treated with dasatinib – interim results from the DAstop2 trial (Source: Leukemia)
Source: Leukemia - January 26, 2024 Category: Hematology Authors: Hjalmar Flygt Stina S öderlund Johan Richter Susanne Saussele Perttu Koskenvesa Leif Stenke Satu Mustjoki Andreja Dimitrijevic Jesper Stentoft Waleed Majeed Lydia Roy Dominik Wolf Arta Dreimane Bj ørn Tore Gjertsen Tobias Gedde-Dahl Erik Ahlstrand Berit Source Type: research
Erythroid variant evolving from chronic myeloid leukemia resistant to multiple tyrosine kinase inhibitors: a rare case report
Chronic myeloid leukemia (CML) is characterized by the presence of BCR::ABL1 fusion gene resulting from a reciprocal translocation, t(9;22)(q34;q11.2), leading to prominent granulocytic proliferation. The majorit... (Source: Diagnostic Pathology)
Source: Diagnostic Pathology - January 24, 2024 Category: Pathology Authors: Michelle Hyunju Lee, Amy Song and Julie Y. Li Tags: Case Report Source Type: research
Long non-coding RNA small nucleolar RNA host gene 29 drives chronic myeloid leukemia progression via microRNA-483-3p/Casitas B-lineage Lymphoma axis-mediated activation of the phosphoinositide 3-kinase/Akt pathway
AbstractThe aberrant expression of the long non-coding RNA (lncRNA) Small Nucleolar RNA Host Gene 29 (SNHG29) has been associated with various human cancers. However, the role of SNHG29 in chronic myeloid leukemia (CML) remains elusive. Therefore, this study aimed to investigate the function of SNHG29 in CML and unveil its potential underlying mechanisms. Herein, peripheral blood samples from 44 CML patients and 17 healthy subjects were collected. The expressions of SNHG29, microRNA-483-3p (miR-483-3p), and Casitas B-lineage Lymphoma (CBL) were measured using quantitative polymerase chain reaction (qPCR) or Western Blot. C...
Source: Medical Oncology - January 22, 2024 Category: Cancer & Oncology Source Type: research
The new Systematic Coronary Risk Evaluation (SCORE2 and SCORE2-OP) estimates the risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib or ponatinib
AbstractPatients with chronic myeloid leukemia (CML) treated with nilotinib or ponatinib may experience arterial occlusive events (AOEs). It is currently recommended to thoroughly assess cardiovascular risk factors before treating CML. We identified 455 consecutive CML adult patients, 335 treated with nilotinib and 120 with ponatinib; 380 patients without previous cardiovascular diseases or diabetes were stratified according to the Systematic Coronary Risk Evaluation (SCORE2) and SCORE2-Older Persons (SCORE2-OP). This updated algorithm from the European Society of Cardiology (ESC) estimates a 10-year risk of fatal and non-...
Source: Annals of Hematology - January 20, 2024 Category: Hematology Source Type: research
